- Introduction to Signatera's personalized ctDNA technology and its differentiation from a generic panel approach.
- Advantages of personalized ctDNA technology in cancer detection in plasma.
- Demonstration of the potential of personalized ctDNA technology in residual disease detection, recurrence monitoring, and treatment response measurement.
- Applications of the technology in oncology research, clinical studies, and pharmaceutical development.
Dr. Jimmy Lin
Chief Scientific Officer, Oncology
Dr. Cheng-Ho Jimmy Lin is leading the development of new diagnostic technologies for cancer. Dr. Lin is also a 2016 Senior TED Fellow and Founder & President of Rare Genomics Institute, the world's first platform to enable any community to leverage cutting- edge biotechnology to advance understanding of any rare disease.